Modern Melanoma Care in Algeria: More Than Immunotherapy

Few malignancies illustrate the transformation of modern oncology as profoundly as melanoma. Within little more than a decade, advances in tumor immunology and molecular oncology have transformed advanced melanoma from a disease with limited systemic options into one in which durable disease control is achievable for selected patients. The updated Algerian National Medical Oncology Therapeutic Guidelines reflect this evolution by embedding precision medicine, immunotherapy, and multidisciplinary care throughout the melanoma treatment pathway.

The management of melanoma has evolved far beyond the introduction of new drugs. Contemporary care increasingly depends on accurate pathological staging, molecular characterization, and individualized therapeutic decision-making. Rather than applying a uniform treatment strategy, clinicians now tailor management according to disease stage, pathological risk factors, molecular profile, and patient characteristics, illustrating the broader transition toward personalized cancer care.

For patients with localized melanoma, complete surgical excision remains the cornerstone of curative treatment. However, surgery alone no longer defines optimal management. Precise pathological evaluation—including assessment of Breslow thickness, ulceration, margin status, and sentinel lymph node involvement when indicated—has become essential, as these factors determine prognosis and increasingly guide subsequent therapeutic decisions. Accurate staging is now the gateway to modern melanoma care.

One of the most significant advances reflected in the updated national recommendations is the expanding role of adjuvant systemic therapy for patients at increased risk of recurrence. Rather than relying solely on postoperative surveillance, eligible patients may benefit from immunotherapy or molecularly targeted therapy according to their clinicopathological and molecular characteristics. This evolution represents a fundamental shift from simply treating recurrence to actively reducing its risk through personalized therapeutic strategies.

The management of advanced melanoma perhaps best illustrates the paradigm shift in contemporary oncology. Therapeutic decisions are no longer centered on selecting the most active cytotoxic regimen but on understanding the biological characteristics of the tumor and matching each patient with the systemic strategy most likely to produce durable clinical benefit. Immune checkpoint inhibitors have become the foundation of treatment for many patients, while molecular testing has become an indispensable component of therapeutic planning. Identification of BRAF mutations directly influences treatment selection, allowing patients with actionable alterations to benefit from BRAF and MEK inhibitor combinations when appropriate. In melanoma, understanding tumor biology has transformed not only the treatments we prescribe but also the outcomes we are able to expect.

As treatment options become increasingly sophisticated, multidisciplinary collaboration has evolved from a desirable practice into an essential component of clinical decision-making. Dermatologists, surgeons, pathologists, radiologists, nuclear medicine physicians, radiation oncologists, and medical oncologists each contribute unique expertise throughout the patient’s journey. Integrating surgical, pathological, radiological, and systemic treatment considerations into a unified management strategy is now fundamental to achieving optimal outcomes.

The successful implementation of these recommendations depends not only on therapeutic availability but also on strengthening pathology services, expanding access to molecular diagnostics, and ensuring timely referral within multidisciplinary cancer centers. As precision oncology continues to evolve, these components will increasingly determine the quality of melanoma care delivered across Algeria. Continued investment in diagnostic infrastructure, specialist training, and clinical research will be essential to ensure equitable access to contemporary standards of care.

Clinical Perspective

Melanoma has become one of the clearest demonstrations that advances in tumor biology can rapidly reshape clinical practice. The updated Algerian National Medical Oncology Therapeutic Guidelines reflect this transformation by integrating precision medicine throughout the patient journey—from diagnosis and pathological assessment to adjuvant treatment and advanced disease management. More importantly, they illustrate a broader evolution in oncology: treatment decisions are no longer driven solely by disease stage but increasingly by the biological characteristics of each tumor and the individual needs of each patient. As access to innovative therapies and molecular diagnostics continues to expand, multidisciplinary expertise and evidence-based implementation will be essential to translating these scientific advances into meaningful improvements in patient outcomes across Algeria.